Xiaomi Watch H1 E: Blood Pressure and Temperature Monitoring
Xiaomi has introduced its first smartwatch capable of continuous blood pressure and wrist temperature monitoring. The device, named Watch H1 E, is already selling in China and is expected to reach other regions soon, according to IT-Home. The wearable sits at the intersection of everyday wellness tracking and convenience, offering users a broad view of vital metrics alongside standard smartwatch features.
At the core of Watch H1 E is the ability to monitor blood pressure throughout the day. A cuff-like inflatable strap wraps the wrist and inflates to measure pressure. During measurements, the user places the hand wearing the watch on the chest and stabilizes the arm with the other hand. This simple setup aims to provide convenient access to important cardiovascular data without requiring a clinic visit.
Xiaomi has certified Watch H1 E as a Class II medical device by the Beijing Municipal Drug Administration. For accurate data, a single daily reading is sufficient, and the watch itself will remind the user when a check is due. Beyond blood pressure, the device also displays pulse rate, blood oxygen saturation, wrist temperature, electrocardiogram data, vascular elasticity, pulse wave, signs of arrhythmia, and a range of additional metrics that health-minded users may find helpful.
The specifications include a 1.43-inch AMOLED display with a resolution of 466 x 466 pixels and a 60 Hz refresh rate, along with an Always On Display mode. The 500 mAh battery supports up to nine days of use on a single charge. The smartwatch enables Wi-Fi, Bluetooth, NFC, and GPS connectivity, and it carries IP68 protection against water and dust, making it suitable for daily wear and active use.
The price of the Watch H1 E in China is 1,900 yuan. This pricing places the device as an accessible option for health tracking, with Xiaomi planning an international rollout to follow. Source: Socialbites.ca
Earlier, details about a Xiaomi flagship featuring a distinctive zoom camera were reported, signaling that the near-term lineup would fuse advanced imaging with expanding health sensing capabilities.